Stockscreener 앱 받기
9.0997
10.43%
0.9997
전일 마감가:
$8.10
열려 있는:
$8.56
하루 거래량:
5.96M
Relative Volume:
1.48
시가총액:
$1.49B
수익:
$1.12B
순이익/손실:
$440.30M
주가수익비율:
3.8226
EPS:
2.3805
순현금흐름:
$-251.02M
1주 성능:
+12.23%
1개월 성능:
+12.23%
6개월 성능:
+17.85%
1년 성능:
+47.36%
1일 변동 폭
$8.3517
$9.13
1주일 범위
$7.812
$8.97
52주 변동 폭
$5.80
$11.97
노바백스 Stock (NVAX) Company Profile
명칭
Novavax Inc
전화
240-268-2000
주소
21 FIRSTFIELD RD, GAITHERSBURG, MD
Compare NVAX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
9.085 | 1.33B | 1.12B | 440.30M | -251.02M | 2.3805 |
VRTX
Vertex Pharmaceuticals Inc
|
426.60 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
723.08 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
809.42 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.45 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.08 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
노바백스 Stock (NVAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-08-28 | 재개 | H.C. Wainwright | Buy |
| 2025-08-20 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-06-17 | 개시 | Citigroup | Sell |
| 2025-02-28 | 개시 | BTIG Research | Buy |
| 2024-07-30 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-05-10 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-05-10 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-08-09 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | 재확인 | B. Riley Securities | Buy |
| 2022-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2022-12-02 | 개시 | Jefferies | Hold |
| 2022-09-22 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-20 | 개시 | BofA Securities | Underperform |
| 2022-02-23 | 재확인 | B. Riley Securities | Buy |
| 2022-02-22 | 재개 | Jefferies | Buy |
| 2022-01-21 | 개시 | Cowen | Outperform |
| 2021-05-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-14 | 개시 | Jefferies | Buy |
| 2020-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-05 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-08-05 | 다운그레이드 | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | 재확인 | B. Riley FBR | Buy |
| 2020-06-29 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-05-28 | 재확인 | B. Riley FBR | Buy |
| 2020-05-12 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-30 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-27 | 재개 | B. Riley FBR | Buy |
| 2019-08-14 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-28 | 다운그레이드 | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-11 | 개시 | Oppenheimer | Outperform |
| 2018-11-26 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2018-03-29 | 업그레이드 | Seaport Global Securities | Neutral → Buy |
모두보기
노바백스 주식(NVAX)의 최신 뉴스
Novavax earnings in focus: Safety edge meets steep revenue test By Investing.com - Investing.com Nigeria
Are These 5 Biotech Stocks Set to Beat Q1 Earnings Estimates? - TradingView
Attachment - GlobeNewswire
Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Is Novavax, Inc. (NVAX) A Good Stock To Buy Now? - Insider Monkey
Vanguard reports 8.31M-share stake in Novavax (NVAX) - Stock Titan
Kura Oncology (KURA) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
Novavax investors get first-quarter 2026 results at 8:30 a.m. May 6 - Stock Titan
Novavax, Inc. (NVAX) is attracting investor attention: Here is what you should know - MSN
Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Novavax (NVAX) director exercises RSUs for 9,520 common shares - Stock Titan
Novavax Inc. stock underperforms Monday when compared to competitors - MarketWatch
Novavax Q2 2025 Earnings Preview - MSN
Bank of America reports 4.1% Novavax stake (NASDAQ: NVAX) - Stock Titan
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Novavax (NASDAQ: NVAX) details 2026 proxy, board slate and equity share increases - Stock Titan
Novavax Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Novavax Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
NVAX stock rises overnight ahead of Q4 print with Pfizer tailwinds — analyst warns of 20% crash - MSN
Novavax Soars After Covid Vaccine Secures Full FDA Approval - MSN
Avoiding Lag: Real-Time Signals in (NVAX) Movement - Stock Traders Daily
Novavax Q3 2025 Earnings Preview - MSN
Cash-Rich Stocks: 10x Genomics, Novavax, and Powell Analysis | April 2026News and Statistics - IndexBox
Is Novavax (NVAX) Now Pricing In Too Much Risk After Its Recent Volatility - Yahoo Finance
Therapeutics Stocks Q4 Earnings: AbbVie and Novavax Performance Analysis as of April 2026News and Statistics - IndexBox
Novavax, Inc. (NVAX) PT Increased as B. Riley Sees Governance-Driven Catalysts Ahead - Insider Monkey
FY2028 EPS Estimates for Novavax Cut by Zacks Research - MarketBeat
1 Cash-Heavy Stock to Target This Week and 2 We Ignore - The Globe and Mail
Novavax (NVAX) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Earnings snapshot: Novavax tops Q2 estimates; raises full-year outlook - MSN
5 Most Undervalued Healthcare Stocks to Buy Now - Insider Monkey
Is Novavax (NVAX) stock a good investment this year | Novavax Inc. posts 122% EPS beat vs expected lossProfit Guidance - Xã Thanh Hà
US CDC will not publish report showing COVID vaccine effectiveness - Reuters
COVID vaccine report on cutting hospital visits blocked from publication in CDC journal - Seeking Alpha
Will Acute Care Strength Help Universal Health Offset Q1 Rising Costs? - TradingView
Will Higher Costs & Lower Occupancy Impact HCA's Q1 Earnings? - TradingView
Therapeutics Q4 Earnings: Novavax (NASDAQ:NVAX) Simply the Best - Yahoo Finance
H.C. Wainwright reiterates Novavax stock rating on vaccine study By Investing.com - Investing.com India
H.C. Wainwright reiterates Novavax stock rating on vaccine study - Investing.com
Is Shah Capital’s Criticism of Novavax Fair? A Wall Street Analyst Weighs In - MedCity News
Novavax’s COVID vaccine becomes 4th available for use in Japan - 朝日新聞
Novavax Urged to Probe Studies Using Monkeys From Filthy Lab After PETA Exposé - PETA
Novavax (NVAX) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Novavax (NVAX) EVP R&D discloses options, RSUs and shares on Form 3 - Stock Titan
Discipline and Rules-Based Execution in NVAX Response - Stock Traders Daily
Novavax Inc stock (US6707721049): Is its vaccine pipeline strong enough to unlock new upside? - AD HOC NEWS
SHAH CAPITAL MANAGEMENT Increases Stake in Novavax Inc - GuruFocus
Novavax Inc stock (US6707721049): Is its vaccine pivot strong enough to unlock new upside? - AD HOC NEWS
노바백스 (NVAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
노바백스 주식 (NVAX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Shiver John W. | Director |
Mar 10 '26 |
Option Exercise |
0.00 |
7,947 |
0 |
7,947 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Mar 07 '26 |
Option Exercise |
0.00 |
12,223 |
0 |
136,503 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Mar 03 '26 |
Option Exercise |
0.00 |
43,167 |
0 |
145,130 |
| Jacobs John C | President and CEO |
Mar 03 '26 |
Option Exercise |
0.00 |
150,167 |
0 |
264,130 |
| O'Hara Elaine | EVP, Chief Strategy Officer |
Mar 03 '26 |
Option Exercise |
0.00 |
56,334 |
0 |
157,071 |
| Casey Mark J | EVP, Chief Legal Officer |
Mar 03 '26 |
Option Exercise |
0.00 |
37,500 |
0 |
101,445 |
| Draghia-Akli Ruxandra | EVP, Research & Development |
Mar 03 '26 |
Option Exercise |
0.00 |
26,667 |
0 |
34,876 |
| Jacobs John C | President and CEO |
Mar 01 '26 |
Option Exercise |
0.00 |
83,333 |
0 |
264,130 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Mar 01 '26 |
Option Exercise |
0.00 |
58,666 |
0 |
130,299 |
| O'Hara Elaine | EVP, Chief Strategy Officer |
Mar 01 '26 |
Option Exercise |
0.00 |
59,600 |
0 |
111,706 |
0.78%
3.01%
자본화:
|
볼륨(24시간):